Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Chronic Pain, Acute Pain, Fatigue, Depre...
Phase NA
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This research study is being done to investigate if the GH Method exercise program positively affects body composition, improves physical abilities and can improve the overall sense of wellbeing (e.g. depression, PTSD, etc.) in U.S. Veterans. Subjects will be asked to complete 94 total visits (four (4) study testing visits and 90 exercise visits). Enrolled subjects will be tested for fitness, strength, and health risk factors at UIC 4 times and will complete 90 exercise training visits at the GH FITLab over the next 18 months. Subjects will also be asked to complete questionnaires about depression, post-traumatic stress symptoms and thoughts about harming oneself.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Investigate the effects of an exercise intervention on U.S. Veterans. — Enrolled subjects will be asked to complete 94 total visits (4 study testing visits and 90 exercise visits). They will be tested for fitness, strength, and health risk factors at UIC 4 times and will complete 90 exercise training visits at the GH FITLab over the next 18 months.

Primary Outcomes

  • Rate at which exercise will change body composition (18 months)
  • Rate at which exercise will change body composition (18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-10-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Illinois at Chicago
Principal Investigators:
  • Enrico Benedetti, MD (PRINCIPAL_INVESTIGATOR) - University of Illinois at Chicago
Contact Information
Study Contact:
Ilaria Santi
312-996-4706
isanti@uic.edu
Natalie Isho, MPH
312-996-4706
nisho@uic.edu
Natalie Isho, MPH
312-996-4706
nisho@uic.edu
University of Illinois at Chicago
Interventions
  • Behavioral: Investigate the effects of an exercise intervention on U.S. Veterans. — Enrolled subjects will be asked to complete 94 total visits (4 study testing visits and 90 exercise visits). They will be tested for fitness, strength, and health risk factors at UIC 4 times and will complete 90 exercise training visits at the GH FITLab over the next 18 months.
Study Locations (1 sites)
University of Illinois at Chicago, Chicago, Illinois 60612 United States
Eligibility Criteria
Inclusion Criteria: * U.S. Veterans * Eligible subjects must be patients at the Jesse Brown VA Medical Center and suffer from pain, fatigue, low energy levels or are unable to physically do things they were once able to do. * Subjects need to complete the PAR-Q with an acceptable score and/or must have written physician clearance. * 18 years of age and older Exclusion Criteria: * Unable to travel to the training center * Unable to give consent * Unable to understand the study * Unable to comply with the training program
Conditions Advanced Prostate Carcinoma, Metastatic ...
Phase PHASE2
Enrollment 210
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial tests how well bright white light (BWL) therapy works in reducing cancer-related fatigue and depression in patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and who are undergoing treatment with antiandrogen therapy (ADT) combination therapy. Combination treatment including ADT plus chemotherapy and androgen receptor (AR) targeted therapy or ADT plus AR targeted therapies work by reducing testosterone. Most prostate tumor cells rely on testosterone to help them grow; therefore, ADT combination therapy causes prostate tumor cells to die or to grow more slowly leading to improved overall survival in men with advanced prostate cancer when compared with ADT alone. However, lower levels of testosterone is also commonly associated with worsening fatigue and depression. If prolonged and severe, these complications can alter patient treatment plans, impacting not just quality of life, but leading to inadequate cancer control. BWL therapy is a type of phototherapy that utilizes bright white full-spectrum light, either through a light box or light therapy glasses to help regulate circadian rhythms. Circadian rhythms are physical, mental, and behavioral changes that follow a 24-hour cycle, including the sleep-wake cycle which can become disrupted in cancer patients undergoing treatment, leading to increased fatigue. Additionally, exposure to bright light may increase the production of serotonin, a neurotransmitter that is associated with mood regulation. BWL therapy with AYOpro light therapy glasses may serve as a supportive care measure for men with advanced prostate to help reduce fatigue, as well as improve mood and overall quality of life during ADT combination therapy to maintain cancer care without suffering complications of therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Procedure: Bright White Light Therapy — Wear AYOpro BWL therapy
  • Drug: Combination Drug Therapy — Receive SOC ADT combination therapy
  • Other: Electronic Health Record Review — Ancillary studies
  • Other: Quality-of-Life Assessment — Ancillary studies
  • Other: Questionnaire Administration — Ancillary studies

Primary Outcomes

  • Change in patient-reported fatigue (Baseline to 3 months post antiandrogen therapy (ADT) combination treatment initiation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-07-09
Completion: 2028-11-30
Eligibility
Age: 60 Years and older
Sex: MALE
Volunteers: false
Enrollment: 210 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • William Dale (PRINCIPAL_INVESTIGATOR) - City of Hope Medical Center
Contact Information
Study Contact:
William Dale
626-256-4673
wdale@coh.org
City of Hope Medical Center
William Dale
City of Hope Medical Center
Interventions
  • Procedure: Bright White Light Therapy — Wear AYOpro BWL therapy
  • Drug: Combination Drug Therapy — Receive SOC ADT combination therapy
  • Other: Electronic Health Record Review — Ancillary studies
  • Other: Quality-of-Life Assessment — Ancillary studies
  • Other: Questionnaire Administration — Ancillary studies
Study Locations (1 sites)
City of Hope Medical Center, Duarte, California 91010 United States
Eligibility Criteria
Inclusion Criteria: * Participants must have histologically or cytologically confirmed prostate cancer * Participants must have radiographic evidence of measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>= 10 mm ( \>= 1 cm) with computed tomography (CT) scan or magnetic resonance imaging (MRI), or metastatic lesions as identified as related to prostate cancer on a standard technetium bone scan. Alternatively patients may have radiographic evidence of metastatic disease on an Axumin or prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) scan * Eligible for treatment with ADT plus docetaxel (planned for 6 cycles or fewer) plus abiraterone acetate and prednisone or darolutamide (triplet therapy), or ADT plus enzalutamide, apalutamide, or darolutamide (doublet therapy). Prior use of ADT with a gonadotropin hormone-releasing hormone (GnRH) agonist or antagonist, or prior orchiectomy is allowed * Age \>= 60 years * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Expected time to next treatment of \>= 12 months and life expectancy of \>= 18 months, as determined by a study Investigator * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Total bilirubin =\< institutional upper limit of normal (ULN) * Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x institutional ULN * Creatinine =\< institutional ULN OR * Glomerular filtration rate (GFR) \>= 50 mL/min/1.73 m\^2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m\^2 * Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better * Ability to understand and the willingness to sign a written informed consent document * Participants are still eligible and may proceed with the protocol and bright white light therapy if they discontinue baseline hormonal treatment, but plan to continue with another of the eligible treatments. However, if they discontinue treatment due to cancer progression, they should not continue on the protocol Exclusion Criteria: * Participants receiving docetaxel cannot have metastatic castration-resistant prostate cancer as the expected median time to progression to next therapy is \< 12 months * Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) with the exception of alopecia * Prior treatment with combination hormonal therapy with abiraterone acetate, enzalutamide, apalutamide, or darolutamide for participants planning to start treatment with abiraterone acetate, enzalutamide, apalutamide, or darolutamide * Participants who are receiving any other investigational agents * Participants with brain metastases are ineligible due to the limited life expectancy of men with prostate cancer metastases to brain * History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in this study * Histologic evidence of small cell prostate cancer * Symptomatic skeletal event complication of prostate cancer such as cord compression, fracture, or need for radiation or surgery to a bone lesion within 6 months * Uncontrolled pain related to prostate cancer or separate chronic condition * Visceral crisis from prostate cancer suggesting rapidly progressive disease and life expectancy of \< 18 months * Participants with uncontrolled intercurrent illness * Concurrent second active malignancy * Severe sleep disorders (e.g. Narcolepsy) * Eye Diseases which limit the ability of light to be processed (e.g. untreated cataracts, severe glaucoma, macular degeneration, blindness, pupil dilation problems or other retinal disorder) * Severe psychological impairment (e.g., bipolar disorder or manic episodes) * Current employment in night shift work * Previous use of light therapy to alleviate fatigue or depressive symptoms * Currently recovering from previous eye surgery within the past 6 months that causes eye irritation * Sensitivity to light, epilepsy, or a history of seizures
Conditions Post-Traumatic Stress Disorder (PTSD), D...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This single-blinded, multicentered, randomized controlled trial aims to evaluate the effectiveness of Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) compared to Treatment-as-Usual (TAU) in reducing post-traumatic stress symptoms among unaccompanied refugee minors (UAMs) residing in accommodation centers and Supported Independent Living (SIL) programs in Greece. Participants aged 15-18 will be randomly assigned to either a TF-CBT intervention group or a TAU control group. The intervention will be delivered by trained psychologists under supervision and culturally adapted to the Greek refugee context. Assessments will occur at baseline, post-intervention, and three months later, using standardized psychometric tools. Secondary outcomes include changes in comorbid psychiatric symptoms (depression, anxiety, somatic symptoms), emotional and behavioral difficulties, and quality of life. The study also investigates potential moderators of treatment response such as age, gender, trauma history, and psychiatric comorbidity.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Trauma - Focused Cognitive Behavioral Therapy — TF-CBT is a comprehensive, evidence-based, short-term therapeutic protocol aimed at reducing trauma-related symptoms in children and adolescents aged 3-18. The protocol consists of 12 double sessions conducted with both the child and their caregiver. Developed for children who have experienced sexual abuse and multiple traumas, TF-CBT has since been successfully applied to a variety of traumatic experiences. Core components of the protocol include psychoeducation, relaxation techniques, emotional regulation, cognitive processing, trauma narrative, in vivo exposure, conjoint child/caregiver sessions, and safety planning. The intervention is culturally informed and flexible to meet individual needs. Adjustments have been made in the context of unaccompanied minors (UAMs), where caregiver involvement is not feasible, due to specific circumstances in accommodation centers and Supportin Greece.
  • Behavioral: Treatment as Usual (TAU) — The Treatment as Usual (TAU) approach involves routine clinical management and psychological support, without the use of a structured therapeutic framework. This intervention consists of general, non-specific support provided by clinical staff, including informal counseling and monitoring of the child's psychological well-being. Unlike more structured therapeutic protocols, TAU does not follow a predefined set of interventions or techniques, allowing for a flexible and individualized approach, though lacking the formal therapeutic focus of interventions like TF-CBT.

Primary Outcomes

  • Child and Adolescent Trauma Screen (CATS) (Initial assessment (baseline), assessment immediately following the intervention, and a follow-up assessment 3 months after the intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-13
Completion: 2026-02
Eligibility
Age: 15 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Theodora Anastasiou
Collaborators: Greek Ministry of Migration and Asylum, SOS Children's Villages
Principal Investigators:
  • Vasiliki Yotsidi, PhD (STUDY_CHAIR) - Panteion University
Contact Information
Study Contact:
Theodora Anastasiou, PhD candidate
+306942883681
theodanastasiou@gmail.com
Theodora Anastasiou, PhD Candidate
+ 30 6942883681
theodanastasiou@gmail.com
General Secretariat for Vulnerable Persons and Institutional Protection, Ministry of Migration and Asylum
Assistant Professon of Clinical Psychology
+30 6937103609
v.yiotsidi@panteion.gr
General Secretariat for Vulnerable Persons and Institutional Protection, Ministry of Migration and Asylum
Interventions
  • Behavioral: Trauma - Focused Cognitive Behavioral Therapy — TF-CBT is a comprehensive, evidence-based, short-term therapeutic protocol aimed at reducing trauma-related symptoms in children and adolescents aged 3-18. The protocol consists of 12 double sessions conducted with both the child and their caregiver. Developed for children who have experienced sexual abuse and multiple traumas, TF-CBT has since been successfully applied to a variety of traumatic experiences. Core components of the protocol include psychoeducation, relaxation techniques, emotional regulation, cognitive processing, trauma narrative, in vivo exposure, conjoint child/caregiver sessions, and safety planning. The intervention is culturally informed and flexible to meet individual needs. Adjustments have been made in the context of unaccompanied minors (UAMs), where caregiver involvement is not feasible, due to specific circumstances in accommodation centers and Supportin Greece.
  • Behavioral: Treatment as Usual (TAU) — The Treatment as Usual (TAU) approach involves routine clinical management and psychological support, without the use of a structured therapeutic framework. This intervention consists of general, non-specific support provided by clinical staff, including informal counseling and monitoring of the child's psychological well-being. Unlike more structured therapeutic protocols, TAU does not follow a predefined set of interventions or techniques, allowing for a flexible and individualized approach, though lacking the formal therapeutic focus of interventions like TF-CBT.
Study Locations (1 sites)
General Secretariat for Vulnerable Persons and Institutional Protection, Ministry of Migration and Asylum, Athens, 182 33 Greece
Eligibility Criteria
Inclusion Criteria: * Be unaccompanied upon arrival in Greece and aged between 15-18 years old. * Being diagnosed with PTSD based on DSM-5 criteria. Young refugees with post-traumatic stress symptoms (PTSS), as delineated by high or moderate trauma-related distress in the Child and Adolescent Trauma Screen (CATS), will also be eligible to participate in the study. * Reside in an accommodation center or SIL program for UAMs in Greece. * Have a stable living arrangement for at least 2-3 weeks prior to the intervention. * Not be expected to relocate within the 2-3 months following the start of the intervention. Exclusion Criteria: * a diagnosed intellectual disability (IQ \< 70) or another developmental disorder * acute suicidality or life-threatening self-harm behavior * significant risk of harm to others * comorbidity with bipolar disorder or a psychotic disorder * substance abuse.
Conditions Obesity, Hyperlipidemias, Polycystic Ova...
Phase NA
Enrollment 95
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Developed nations worldwide are currently enduring a health crisis, as chronic diseases continue to decrease quality of life and promote additional disease states or even death for much of the population. Rural populations are at a particular disadvantage, as they lack access to health clubs, wellness programs and similar resources that are more available in urban areas. Although pharmaceutical therapies have continued to show therapeutic advancements, the rates of disease onset and death from chronic disease has not seen similar improvements, and in fact continue to worsen. Excitingly, significant evidence has been published demonstrating an affordable, effective treatment to directly treat and prevent these chronic diseases, but few have demonstrated successful implementation of this therapy, which is improved lifestyle. Specifically, physical activity and healthy body composition are powerful therapeutics that have been demonstrated to effectively combat and prevent chronic diseases. Additionally, improving these lifestyle factors are often more effective than pharmaceutical interventions without the wide range of side effects. Unfortunately, barriers exist on multiple tiers in the practice of family medicine that demote the implementation of lifestyle medicine. To better serve patients at risk of, or suffering from chronic disease, the investigators are seeking to establish a lifestyle medicine prescription program for rural West Virginia. This program will provide patient education on the benefits of physical activity, body composition, and help patients identify strategies to implement healthy lifestyle choices that can be sustainable for the long-term. Patients will be advised on local opportunities to increase physical activity (yoga studio, martial arts, fitness facilities, aquatic center, etc.) and provided access to the facilities they are most likely to adhere to regularly. They will also be provided training on exercise techniques, equipment, and facilities to increase familiarity and comfort in these settings.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Lifestyle counseling and coaching — Each participant will be provided with personalized exercise therapy that is best suited for their personal goals and disease states. Participants in this study will be encouraged to establish accountability through setting SMART goals, and through monitoring their activity using wearable fitness technology provided to them. This program will also aim to create a sense of community as group activity classes will be available for those that wish to attend. Individualized exercise/physical activity prescriptions will be provided and discussed.

Primary Outcomes

  • Demand (1 month)
  • Attrition rate (4 months)
  • physical activity (4 months)
  • Body Composition (Once at enrollment, and once at cessation of the intervention 4 weeks later.)
  • Body Composition (Once at enrollment, and once at cessation of the intervention 4 weeks later.)
  • Body Composition (Once at enrollment, and once at cessation of the intervention 4 weeks later.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-01
Completion: 2027-09-01
Eligibility
Age: 18 Years – 64 Years
Sex: ALL
Volunteers: false
Enrollment: 95 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: West Virginia School of Osteopathic Medicine
Principal Investigators:
  • Christopher L Pankey, Ph.D. (PRINCIPAL_INVESTIGATOR) - West Virginia School of Osteopathic Medicine
Contact Information
Study Contact:
Christopher L Pankey, Ph.D.
3047936576
cpankey@osteo.wvsom.edu
Dovenia Ponnoth, Ph.D.
3046476297
dponnoth@osteo.wvsom.edu
West Virginia School of Osteopathic Medicine
Peter Feltman
3046476284
pfeltman@osteo.wvsom.edu
West Virginia School of Osteopathic Medicine
Interventions
  • Behavioral: Lifestyle counseling and coaching — Each participant will be provided with personalized exercise therapy that is best suited for their personal goals and disease states. Participants in this study will be encouraged to establish accountability through setting SMART goals, and through monitoring their activity using wearable fitness technology provided to them. This program will also aim to create a sense of community as group activity classes will be available for those that wish to attend. Individualized exercise/physical activity prescriptions will be provided and discussed.
Study Locations (1 sites)
West Virginia School of Osteopathic Medicine, Lewisburg, West Virginia 24901 United States
Eligibility Criteria
Inclusion Criteria: * Program admittance will be restricted to patients with 2+ diagnosed diseases that have sufficient evidence for the efficacy of exercise therapy (obesity, hyperlipidemia, metabolic syndrome, polycystic ovarian syndrome, type II diabetes, hypertension, coronary heart disease, heart failure, depression, anxiety) * physician referral required Exclusion Criteria: * no chronic disease diagnosis, lack of physician referral, unwillingness to participate.
Conditions All Cause Mortality, Cardiovascular Dise...
Phase NA
Enrollment 10000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test two advices on alcohol drinking in more than 10.000 Spanish adult drinkers (men of 50 or more years and women of 55 or more years). The main question it aims to answer is to test the non-inferiority advice of a moderate alcohol drinking pattern on all-cause mortality and other chronic disease like cardiovascular disease, cancer or type 2 diabetes. Participants will receive during 4 years an advice to drink alcohol following a Mediterranean Alcohol Drinking Pattern (MADP): consuming alcohol in moderation, avoidance of binge drinking and preference for red wine. Researchers will compare those who will receive a MADP advice with those who will receive an advice on abstention to see if the advice on MADP is not inferior than the abstention advice to prevent all-cause mortality and other chronic diseases.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Moderate Alcohol Drinking Pattern — Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months. Goals of intervention: 1. moderate consumption (7 or less drinks/wk for women, 14 or less drinks/wk for men) of red wine (a drink=150 ml). 2. always during meals 3. spread out throughout the whole week, and 4. avoidance of binge-drinking episodes. No participant will be invited to start or increase his/her alcohol intake.
  • Behavioral: Abstention — Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months. Goals of intervention: Abstention. Message of 0 alcohol.

Primary Outcomes

  • Comparison between groups of the incidence of a global Index of all-cause mortality and other alcohol-related diseases (From enrollment to the end of the intervention up to 4 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-15
Completion: 2029-06-30
Eligibility
Age: 50 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Principal Investigators:
  • Miguel A Martinez-Gonzalez, MD, MPH, PhD (PRINCIPAL_INVESTIGATOR) - University of Navarra
Contact Information
Study Contact:
Miguel A Martinez-Gonzalez, MD, MPH, PhD
+34948425600
mamartinez@unav.es
Maira Bes-Rastrollo, PharmD, PhD
+34948425600
mbes@unav.es
Estíbaliz Goñi, Nutritionist
34948425600
egonioch@unav.es
University of Navarra
Interventions
  • Behavioral: Moderate Alcohol Drinking Pattern — Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months. Goals of intervention: 1. moderate consumption (7 or less drinks/wk for women, 14 or less drinks/wk for men) of red wine (a drink=150 ml). 2. always during meals 3. spread out throughout the whole week, and 4. avoidance of binge-drinking episodes. No participant will be invited to start or increase his/her alcohol intake.
  • Behavioral: Abstention — Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months. Goals of intervention: Abstention. Message of 0 alcohol.
Study Locations (1 sites)
University of Navarra, Pamplona, Navarre 31008 Spain
Eligibility Criteria
Inclusion Criteria: * Males aged 50-70 years, Women aged 55-75 years * Drinkers of any alcoholic beverage initially consuming 3 or more but 40 or less drinks/wk * Projected life expectancy more than 5 years (according to the judgment of their attending physician) * Willing to receive advice during up to 4 years on how to improve their alcohol intake making it healthier Exclusion Criteria: 1. Participants without smartphone or a computer (or tablet) with Internet connection. 2. Drinkers of less than 30 g of pure alcohol/wk or more than 400 g of pure alcohol/wk 3. Illiteracy, inability/unwillingness to give written consent or communicate with study staff, or inadequate abilities for the use of on-line technologies 4. Participants with any sever psychiatric condition or with a diagnosis of cognitive impairment or dementia. 5. Participants with liver cirrhosis or prior liver cancer. 6. Patients with a recent diagnosis of breast cancer (diagnosed in the last 10 years). 7. Patients under habitual use of high-dose medications that completely preclude any use of alcohol. Most of these patients will be already excluded by the second or fourth exclusion criteria.

Pain and Major Depressive Disorder

NCT04556890
Recruiting
Conditions Major Depressive Disorder, Chronic Pain
Phase NA
Enrollment 54
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This study will examine the effects of brain stimulation on pain symptoms associated with Major depressive disorder. This study will enroll 54 Subjects. Study subjects will be asked to complete surveys about their mood and well-being, 2 blood draws, 2 MRIs, 3 electroencephalograms, and receive 30 treatments of blinded transcranial magnetic stimulation. There is no control group as all subjects will receive some form of active treatment. Subjects are required to participate in 30-33 study visits and volunteer 40 hours of their time. Compensation for this study is $150 for completing all study activities.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Active rTMS/Active iTBS DFPLC/Sham Pain M1 — Active rTMS treatment for depression (600 pulses of active intermittent theta burst (iTBS) administrated at 120% MT to the left DLPFC) and sham treatment for pain at M1
  • Device: Active rTMS/Active iTBS — Active rTMS treatment for both, depression and pain (600 pulses of iTBS to left DLPFC followed by 600 iTBS + 1500 pulses of 10 Hz to M1

Primary Outcomes

  • Percent change in depression scores (Through study completion, an average of 6 weeks)
  • Percent change in pain score (Through study completion, an average of 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-01
Completion: 2027-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 54 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Los Angeles
Contact Information
Study Contact:
Doan Ngo, BS
310-825-7797
thucdoanngo@mednet.ucla.edu
Juliana Corlier, PhD
jcorlier@ucla.edu
THUC-DOAN NGO, BS
3108257797
thucdoanngo@mednet.ucla.edu
UCLA Semel Institute
Interventions
  • Device: Active rTMS/Active iTBS DFPLC/Sham Pain M1 — Active rTMS treatment for depression (600 pulses of active intermittent theta burst (iTBS) administrated at 120% MT to the left DLPFC) and sham treatment for pain at M1
  • Device: Active rTMS/Active iTBS — Active rTMS treatment for both, depression and pain (600 pulses of iTBS to left DLPFC followed by 600 iTBS + 1500 pulses of 10 Hz to M1
Study Locations (1 sites)
UCLA Semel Institute, Los Angeles, California 90024 United States
Eligibility Criteria
Inclusion Criteria: * All Subjects must be between 18-75 years of age * Language: Participants must speak English fluently, as demonstrated by verbal skills sufficient to answer questions at a level that assures adequate understanding of the study * Must have confirmed diagnosis of moderate Major Depressive Disorder (single or recurrent episode), minimum score of 17 on the 17-item Hamilton Rating Scale for Depression (HAM-D17). No minimal MDD duration necessary for study participation * Failure to respond to a minimum of 2 trials of antidepressant medication * Failure to respond from at least two different agent classes * Accompanied by at least two evidence-based augmentation therapies (Benzodiazepines do not count) * Must have a trial of psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration\* * Must have a confirmed FM or ME/CFS diagnoses and moderate pain complaints, minimum score of 15 on the McGill Pain Questionnaire. * Pain chronicity for at least 3 months prior to study enrollment. * Subjects are willing and able to adhere to the treatment schedule and required study visits. Exclusion Criteria: * Are mentally or legally incapacitated, unable to give informed consent. * Are pregnant. * Have an active suicidal intent or plan. * Have had prior Transcranial Magnetic Stimulation treatment. * Have an infection or poor skin condition over the scalp where the device will be positioned. * Have increased risk of seizure because of family history, stroke, or currently use medications that lead to increased risk for seizure. * Psychotic depression or other acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode. * Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system. * Presence of an implanted metallic and magnetic-sensitive medical device present in the body scan, including but not limited to a cochlear implant, infusion pump, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, aneurysm clip, metal prosthesis, or metal aneurysm clips or coils, staples, or stents. (Note: Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with transcranial magnetic stimulation and MRI)
Conditions Major Depressive Disorder
Phase PHASE4
Enrollment 162
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this naturalistic, open label, single arm intervention study is to investigate the effects of Esketamine in treating depression.The main aims to answer are: * to investigate whether Esketamine is effective when added to ongoing antidepressant treatment * to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice Participants will: * attend the clinic for supervised self-administration of intranasal Esketamine treatment * be observed for 2 hours following Esketamine administration including blood pressure monitoring * be asked to complete a battery of questionnaires * be reimbursed for travel expenses

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Esketamine Nasal Spray [Spravato] — This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.

Primary Outcomes

  • Percentage of treatment responders determined by a 50% reduction on the Hamilton Depression Rating Scale (HAM-D) 17-Item scoring. (At the end of week 4)
  • Mean depression score on the Quick Inventory of Depressive Symptomatology Self-report (QIDS-SR) 16-Item. (Baseline, at the end of weeks 1,2,3, and 4 (primary time point); and further after week 8 and week 12 after Esketamine was commenced.)
  • Global functioning determined by Clinical Global Impression (CGI) score. (Baseline, week 1, week 2, week 3, week 4 (primary time point), week 8 and week 12 after Esketamine was commenced.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2023-10-31
Completion: 2028-08-15
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 162 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Royal North Shore Hospital
Collaborators: Janssen-Cilag Pty Ltd
Principal Investigators:
  • Gin Malhi (PRINCIPAL_INVESTIGATOR) - Royal North Shore Hospital, University of Sydney
Contact Information
Study Contact:
Erica Bell
02 9462 9905
NSLHD-researchpoet@health.nsw.gov.au
Yan Yau Wong
NSLHD-researchpoet@health.nsw.gov.au
Erica Bell
02 9462 9905
NSLHD-researchpoet@health.nsw.gov.au
Royal North Shore Hospital
Interventions
  • Drug: Esketamine Nasal Spray [Spravato] — This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.
Study Locations (1 sites)
Royal North Shore Hospital, St Leonards, New South Wales 2065 Australia
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 18-65 years old 2. Diagnosis of Major Depressive Disorder (MDD) 3. Currently depressed 4. Had an inadequate response to 2 or more courses of antidepressants (of adequate dose and duration) 5. Be maintained on their current antidepressant medication or psychological therapy at the time of enmrolment 6. Able to understand and provide informed consent Exclusion Criteria: 1. Concurrent diagnoses: * Participants with other 'Diagnostic and Statistical Manual of Mental Disorders' (DSM-5) e.g., current substance misuse disorder, bipolar disorder, schizophrenia * Participants who are unable to understand the study and therefore unable to provide informed consent 2. Pregnancy: * Participants who are pregnant and/or breastfeeding * Participants who are not willing to avoid pregnancy for themselves or their partners during the study by using effective birth control methods 3. Current medications: * Participants taking a total daily dose of benzodiazepines greater than the equivalent of 6mg/day of lorazepam * Participants on complementary and alternative medicine therapies i.e., St John's wort, Chinese medicines, and various herbal and homeopathic treatments 4. Stimulants * Participants taking stimulants such as methylphenidate, amphetamine, and dextroamphetamine for a diagnosis such as ADHD can still have Esketamine provided they do not continue taking stimulants concurrently for the duration of the study. * Concurrent use is excluded due to the synergistic effect with Esketamine that can cause increased blood pressure. 5. Medical history: * Participants with current or past history of seizures (uncomplicated childhood febrile seizures with no sequelae are not exclusionary) * Participants with a history of uncontrolled hypertension * Participants with uncontrolled diabetes mellitus * Participants with aneurysmal vascular disease including thoracic and abdominal aorta, intracranial and peripheral arterial vessels, or arteriovenous malformation, intracerebral haemorrhage * Participants with untreated glaucoma, current penetrating or perforating eye injury, brain injury, hypertensive encephalopathy, intrathecal therapy with ventricular shunts, or any other condition associated with increased intracranial pressure or increased intraocular pressure or planned eye surgery * Participants who are currently receiving electroconvulsive therapy (ECT) or have received ECT in the past month. 6. Substance Misuse History: * Participants who have ever had a substance misuse disorder involving any of the following over their lifetime: ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-methamphetamine (MDMA), or other hallucinogen use history * Participants with hypersensitivity to Esketamine, Ketamine, or any of the excipients
Conditions Depression, Cannabis Use Disorder, HIV
Phase NA
Enrollment 280
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

To elucidate mechanisms of substance use disorders (SUD) and comorbid mental illnesses in people living with HIV (PLWH), the study team seeks to investigate reward and pain circuitry in cannabis use and depression comorbidity, two highly prevalent conditions in PLWH. The study team proposes a tightly integrative study to test the overall hypothesis that cannabis use and depression in young PLWH have an additive effect, inducing both reward deficits and pain hypersensitivity, and that this pattern will predict worse outcomes at 1 year follow-up.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: MRI Study — fMRI Tasks

Primary Outcomes

  • Addiction Severity Index (ASI) (Up to 1 year)
  • Montgomery Asberg Depression Rating Scale (MADRS) Scale (Up to 12 months)
  • Temporal Experience of Pleasure Scale (TEPS) (Up to 12 months)
  • Neural Circuitry measured by MRI (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-04-01
Completion: 2027-07-30
Eligibility
Age: 18 Years – 59 Years
Sex: ALL
Volunteers: false
Enrollment: 280 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Miami
Collaborators: National Institute on Drug Abuse (NIDA)
Principal Investigators:
  • Vilma Gabbay, MD (PRINCIPAL_INVESTIGATOR) - University of Miami
Contact Information
Study Contact:
Vilma Gabbay, MD
305-243-2382
vxg595@med.miami.edu
Jasmine Agreda, BS
305-243-5510
jja145@med.miami.edu
University of Miami
Joanna Starrels, MD
University of Miami
Interventions
  • Behavioral: MRI Study — fMRI Tasks
Study Locations (1 sites)
University of Miami, Miami, Florida 33136 United States
Eligibility Criteria
Inclusion Criteria: * HIV seropositivity confirmed with lab report, medical records, or HIV testing. * Between the ages of 18-39 years * Fluency in English or Spanish * Ability to provide informed consent and perform study procedures, including estimated full-scale intelligence quotient (IQ) \>75 to ensure that participants are able to understand the study. * Cannabis users: To capture a wide range of cannabis use frequency, meeting Diagnostic and Statistical Manual 5 (DSM-5) criteria for Cannabis use Disorder (CUD) will not be required. However, in order to ensure sufficient exposure, cannabis use will be significant (self-reported use on ≥20 of the prior 30 days and positive THC urine toxicology). * Depressed: In order to capture a wide range of depression illness severity, we will allow participants with subthreshold depression, defined as a raw severity score of ≥12 on the Montgomery Asberg Depression Rating Scale (MADRS). Exclusion Criteria: * Perinatally acquired HIV infection, as early neurodevelopmental alterations and HIV legacy effects may exist in this group * Pregnancy or lactation * Current Substance Use Disorder other than cannabis or nicotine * Certified for or self-reported medical cannabis use, or intent to become certified * Current cocaine use by self-report or urine toxicology * central nervous system (CNS) disease or injury, or neuro-degenerative disease * Unique pain syndromes (e.g. multiple sclerosis, rheumatoid arthritis); * Severe medical illness such as end-stage renal disease, heart failure, cirrhosis, or cancer * MRI contraindication such as claustrophobia, metallic ink tattoos, or pacemaker. Depressed cannabis non-users: * At baseline, all participants will be psychotropic-medication-free for ≥1 month prior to study enrollment (or ≥3 months for medications with longer half-lives). Benzodiazepines and sleeping aids taken on an as-needed basis will be allowed, however we will require a 4-day abstinence period before the scan. * Exclusionary are participants with a DSM-5 diagnoses of bipolar disorder, psychotic disorders, autism spectrum disorders, and all non-cannabis substance-related disorders will be exclusionary. disorder (PTSD) are not uncommon among depressed individuals and will be * Anxiety disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress are allowed as long as depressive symptoms are primary. atypical of depression. • Suicidal ideations (SI) without a specific plan (defined as passive SI) are common in depression and will be allowed. However, if SI constitutes an imminent risk to self or others (defined as active SI), the participant will be withdrawn from the study and emergency procedures will be initiated immediately, including ER admission. Depressed cannabis users: • Exclusion criteria will be the same as depressed cannabis non-users except for cannabis use. Non-depressed cannabis users: • Will have no major psychiatric conditions other than cannabis use/disorder. Non-depressed cannabis non-users: • Exclusion criteria will be the same as for non-depressed cannabis users; in addition participants will not report cannabis use in the prior 90 days and have a urine toxicology test negative for cannabis.
Conditions Cancer
Phase NA
Enrollment 248
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to examine the effectiveness of Digital storytelling (DST) in reducing depressive symptoms, enhancing self-esteem, and promoting quality of life among Chinese survivors of childhood cancer. Participants in the experimental group will be divided into groups of 6 to 8 childhood cancer survivors to receive the intervention, which comprises four workshops. Each workshop will last 2.5 hours and will be conducted by a qualified interventionist. Parents are not required to attend the workshop. The investigators will provide a waiting room for them. Parents will also be provided with a leaflet developed by Hong Kong Department of Health which contains self-help material for depression. No intervention will be carried out among participants in the control group. However, customary care including medical follow-up, medication prescription, and nursing interventions will be provided, as usual. Parents will also be provided with a leaflet containing self-help materials for depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Digital storytelling — DST is an intervention that can potentially mitigate the psychological impact of traumatic experiences. People can usually find positive meaning in a traumatic experience by communicating their experience using narratives like storytelling. In particular, by externalising the traumatic experience in the form of a narrative, the individual can become an objective agent, distancing themselves from negative meanings attached to the experience. This lowers people's resistance to and defence against the experience, assisting them to explore alternative perspectives regarding the experience and to identify its positive aspects, which boost self-esteem. Likewise, storytelling engages different areas of the brain, including those responsible for visual, language, and hearing functions, to reorganise the disorganised traumatic experience into a coherent story, facilitating integration of the experience into existing memories.

Primary Outcomes

  • Depressive symptoms: Chinese version of the Center for Epidemiological Studies Depression Scale for Children (CES-DC) (The CES-DC will be conducted immediately after the completion of the intervention, and at 1-, 3- and 6-month follow-up via telephone interview.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-16
Completion: 2026-09-12
Eligibility
Age: 13 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 248 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Hong Kong Polytechnic University
Collaborators: Hong Kong Children's Hospital, Research Grants Council, Hong Kong
Principal Investigators:
  • Ka Yan Ho, phd (PRINCIPAL_INVESTIGATOR) - The Hong Kong Polytechnic University
Contact Information
Study Contact:
Ka Yan Ho, PhD
+8527666417
kyeva.ho@polyu.edu.hk
Ting MAO
66754757
23040516R@connect.polyu.hk
The Hong Kong Polytechnic University,
Interventions
  • Other: Digital storytelling — DST is an intervention that can potentially mitigate the psychological impact of traumatic experiences. People can usually find positive meaning in a traumatic experience by communicating their experience using narratives like storytelling. In particular, by externalising the traumatic experience in the form of a narrative, the individual can become an objective agent, distancing themselves from negative meanings attached to the experience. This lowers people's resistance to and defence against the experience, assisting them to explore alternative perspectives regarding the experience and to identify its positive aspects, which boost self-esteem. Likewise, storytelling engages different areas of the brain, including those responsible for visual, language, and hearing functions, to reorganise the disorganised traumatic experience into a coherent story, facilitating integration of the experience into existing memories.
Study Locations (1 sites)
The Hong Kong Polytechnic University,, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * (1) age between 13 and 18 years; * (2) able to speak Cantonese and read Chinese; and * (3) completed the active treatment of cancer. Exclusion Criteria: * survivors with mental and behavioural problems documented in their medical records.
Conditions Perimenopause, PMDD
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Transcutaneous Auricular Neurostimulation (tAN) will be administered to women with premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and perimenopause. The investigators will examine whether tAN improves symptomology by collecting self-report data before the intervention, during the intervention, and following the intervention.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: transcutaneous auricular neurostimulation (tAN) — Device: Sparrow Link. The Sparrow Link will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. This device will stimulate the auriculotemporal nerve (ATN) and the auricular branch of the vagus nerve (ABVN)

Primary Outcomes

  • Daily Record of Severity of Problems (DRSP) (Assessed daily from study initiation until the end of the study, an average of four months (4 cycles). Menstrual cycle length varies but is generally 21-35 days.)
  • Green Climacteric Scale (Participants will complete this measure monthly from study initiation until the end of the study, about three months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-10
Completion: 2027-03
Eligibility
Age: 18 Years – 55 Years
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Texas Christian University
Collaborators: Spark Biomedical, Inc.
Principal Investigators:
  • Sarah E Hill, PhD (PRINCIPAL_INVESTIGATOR) - Texas Christian University
Contact Information
Study Contact:
Sarah E Hill, PhD
817-257-6424
s.e.hill@tcu.edu
Savannah A Hastings, M.S.
817-257-4989
s.a.hastings@tcu.edu
Sarah E Hill, PhD
817-257-6424
s.e.hill@tcu.edu
Texas Christian University
Interventions
  • Device: transcutaneous auricular neurostimulation (tAN) — Device: Sparrow Link. The Sparrow Link will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. This device will stimulate the auriculotemporal nerve (ATN) and the auricular branch of the vagus nerve (ABVN)
Study Locations (1 sites)
Texas Christian University, Fort Worth, Texas 76109 United States
Eligibility Criteria
PMS/PMDD Study: Inclusion Criteria: * Assigned female at birth * Age 18 to 45 * Naturally cycling * Regularly occurring menstrual cycle * Must identify as having PMS or PMDD * Reliable ability to complete online study surveys Exclusion Criteria: * Using hormonal birth control * Pregnant or lactating/breastfeeding * History of seizures * Implanted devices * Current or previous diagnosis of any heart conditions * Abnormal ear anatomy * Non-removable piercings on the ear * Recent ear infection * Taking SSRIs * Taking steroids * Taking hormone therapy * If the participant anticipates starting or stopping prescription medications during the study period * Participant has a history of neurologic diseases (i.e. stroke, brain tumor, cerebrovascular, etc.) * Participant has a history traumatic brain injury within the past 12 months * Must not have any other mental illness or mood disorder Perimenopause Study: Inclusion Criteria: * Assigned female at birth. * Age 40 to 55 * Must have newly variable menstrual cycles or report identifying as perimenopausal * Reliable ability to complete online study surveys Exclusion Criteria: * Using hormonal birth control * Pregnant or lactating/breastfeeding * History of seizures * Implanted devices * Current or previous diagnosis of any heart conditions * Abnormal ear anatomy * Non-removable piercings on the ear * Recent ear infection * Taking SSRIs * Taking steroids * Taking hormone therapy * If the participant anticipates starting or stopping prescription medications during the study period. * Participant has a history of neurologic diseases (i.e. stroke, brain tumor, cerebrovascular, etc.) * Participant has a history traumatic brain injury within the past 12 months * have a hysterectomy In both studies we will confirm that participants are symptomatic shortly following enrollment.
Conditions Hypertension
Phase NA
Enrollment 390
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Background: Isometric resistance exercises (IREs) have great potential to improve blood pressure (BP) control. However, the effectiveness of IREs in reducing HT is still unknown because their hypotensive effects have not been detected using ambulatory BP measurements (ABPM), which are the current standard for BP measurement. Methods: This first adequately-powered RCT will involve 390 patients with HT who do not meet the current physical activity guidelines defined by the World Health Organization. Participants will be randomly assigned in a 1:1 ratio using stratified and blocked randomization to either the IRE (wall squat) group or stretching exercise (active control) group. A well-structured, widely accepted, and validated 24-week wall squat program (2 minutes per exercise, 2 minutes of rest between sets, and 3 sessions per week) will be implemented, as it has been commonly used in previous research. Adherence to the program will be monitored using smartwatches, and regular contact with patients through social media will help ensure adherence. All patients will be followed up for 1 year to investigate the long-term effects of IREs on BP. Control group will receive exact same treatment except that IRE is replaced by frequency-matched and time-matched stretching exercise. The primary outcome measure will be systolic daytime ABPM BP at 24 weeks. Secondary outcome measures will include other BP and ABPM parameters at 12 weeks, 24weeks and 1year, cfPWV at baseline, 24 weeks and 1year, and FMD at baseline and 24weeks. Safety data will be collected and reported.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: isometric wall exercise — Each exercise session will contain 4 sets of 2-minute wall squat isometric holds with 2 minutes of rest between each set (approximately 14 minutes per session in total), and a total of 3 sessions will be arranged every week (with ideally 48 h between exercises)
  • Behavioral: passive stretching — A frequency-matched (3x/week) and time-matched (\~14 minutes each session) passive static stretching exercise will be used

Primary Outcomes

  • daytime systolic blood pressure (BP) assessed via ambulatory blood pressure monitoring (ABPM) (24-week after recruitment (immediate post-intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2027-09-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 390 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Contact Information
Study Contact:
Eric Kam-Pui Lee, MSc, FRACGP
22528462
lkp032@cuhk.edu.hk
Eric Kam-Pui Prof Lee
22528462
lkp032@cuhk.edu.hk
Lek Yuen General Outpatient Clinic
kam pui Lee, Msc
85260996560
lkp032@cuhk.edu.hk
School of public health and primary care
Interventions
  • Behavioral: isometric wall exercise — Each exercise session will contain 4 sets of 2-minute wall squat isometric holds with 2 minutes of rest between each set (approximately 14 minutes per session in total), and a total of 3 sessions will be arranged every week (with ideally 48 h between exercises)
  • Behavioral: passive stretching — A frequency-matched (3x/week) and time-matched (\~14 minutes each session) passive static stretching exercise will be used
Study Locations (2 sites)
Lek Yuen General Outpatient Clinic, Hong Kong, 00000 Hong Kong
School of public health and primary care, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * a suboptimal daytime SBP of \>135-160 mmHg on a 24-h ABPM * reported no regular physical activity or less than that recommended for adults by the World Health Organization (e.g. \<150 minutes of moderate-intensity aerobic exercise per week) * on stable doses of anti-HT medication(s) for ≥4 weeks if the patient is receiving drug treatments; * agree for no drug changes during the intervention period (24 weeks); Exclusion Criteria: * cannot provide informed consent * unwillingness to repeat ABPM * relative contraindications to ABPM (i.e. diagnosed atrial fibrillation, nighttime workers, occupational drivers, or patients with bleeding tendencies) * severe osteoarthritis pending knee replacement surgery * known secondary HT * use of ≥3 anti-HT medications at maximum doses or ≥4 anti-HT medications * SBP or DBP are \>160 mmHg or \>100 mmHg, respectively, on ABPM at baseline or at 12 weeks follow-up to ensure safety * pregnancy/breastfeeding * active malignancy
Conditions Advanced Chronic Liver Disease
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to assess non-invasive tools' efficacy in predicting portal hypertension-related complications in individuals with advanced chronic liver disease. The main question it aims to answer are: \- what are the cut-off values for non-invasive tests (NITs) (including LSM, SSM) that predict the presence and occurrence of hepatic decompensation in individuals with advanced chronic liver disease? Participants will undergo regular study visits involving non-invasive tests (LSM, SSM) and assessments to monitor hepatic decompensation over the study period.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Number of patients diagnosed with portal hypertension using elastography techniques (At baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-10
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact Information
Study Contact:
Amine Benmassaoud, MD
514-934-1934
amine.benmassaoud@mcgill.ca
Olivia Geraci, BSc
514-934-1934
olivia.geraci@muhc.mcgill.ca
Amine Benmassaoud, MD
5149341934
amine.benmassaoud@mcgill.ca
McGill University Health Centre
Interventions
N/A
Study Locations (1 sites)
McGill University Health Centre, Montreal, Quebec H3G1A4 Canada
Eligibility Criteria
Inclusion Criteria: * Age above 18years old * Advanced chronic liver disease (defined as LSM ≥ 10kPa) * Ability to provide informed consent Exclusion Criteria: * Transjugular intrahepatic portosystemic shunt * previous liver transplantation * Abnormality of the porto-mesenteric system (portal vein thrombosis, splenic vein thrombosis, splenectomy, portal cavernomatous transformation, porto-caval shunts) * Hematological malignancy